A phase II, single-centre, randomised study of the effectiveness of the addition of Capecitabine to a standard regimen containing Adriamycin, Cyclophosphamide and Docetaxel as neoadjuvant treatment in large or locally advanced breast cancers.

Trial Profile

A phase II, single-centre, randomised study of the effectiveness of the addition of Capecitabine to a standard regimen containing Adriamycin, Cyclophosphamide and Docetaxel as neoadjuvant treatment in large or locally advanced breast cancers.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Capecitabine (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
  • Indications Advanced breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms XINACT
  • Most Recent Events

    • 01 Jan 2012 Actual end date (Dec 2011 ) added as reported by ISRCTN: Current Controlled Trials.
    • 31 Dec 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials
    • 05 Oct 2011 Status changed from active, no longer recruiting to recruiting as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top